Comparative Pharmacology
Head-to-head clinical analysis: RENVELA versus VELPHORO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RENVELA versus VELPHORO.
RENVELA vs VELPHORO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Renvela (sevelamer carbonate) is a phosphate-binding polymer that binds dietary phosphate in the gastrointestinal tract, inhibiting phosphate absorption and reducing serum phosphate levels. It also binds bile acids, leading to decreased LDL cholesterol.
Iron-based phosphate binder that forms non-absorbable complexes with dietary phosphate in the gastrointestinal tract, reducing serum phosphate levels.
Adults: 800 mg orally three times daily with meals; titrate based on serum phosphorus levels up to 2400 mg per meal (7200 mg/day maximum).
1-2 tablets (500-1000 mg iron) orally three times daily with meals; titrate to achieve serum phosphorus target.
None Documented
None Documented
Not applicable as sevelamer is not absorbed. No systemic half-life; local gastrointestinal transit time is approximately 3-4 hours.
Not applicable (non-absorbed drug acting locally in GI tract; no systemic half-life).
Sevelamer carbonate is not absorbed systemically; excretion is entirely fecal as the parent compound. Less than 0.01% is absorbed and excreted renally.
Primarily fecal as unabsorbed drug; negligible renal excretion (<0.1%).
Category C
Category C
Phosphate Binder
Phosphate Binder